203 related articles for article (PubMed ID: 11368265)
1. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase.
Zehtab T; Yazdanparast R; Rafieii S
Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265
[TBL] [Abstract][Full Text] [Related]
2. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
3. Why tyrosinase for treatment of melanoma.
Song YH
Lancet; 1997 Jul; 350(9071):82-3. PubMed ID: 9228956
[No Abstract] [Full Text] [Related]
4. Autoimmune response against tyrosinase induces depigmentation in C57BL/6 black mice.
Al Robaee AA; Alzolibani AA; Rasheed Z
Autoimmunity; 2020 Dec; 53(8):459-466. PubMed ID: 33084421
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinase as an autoantigen in patients with vitiligo.
Baharav E; Merimski O; Shoenfeld Y; Zigelman R; Gilbrud B; Yecheskel G; Youinou P; Fishman P
Clin Exp Immunol; 1996 Jul; 105(1):84-8. PubMed ID: 8697641
[TBL] [Abstract][Full Text] [Related]
6. The role of tyrosinase in autoimmune vitiligo.
Song YH; Connor E; Li Y; Zorovich B; Balducci P; Maclaren N
Lancet; 1994 Oct; 344(8929):1049-52. PubMed ID: 7934446
[TBL] [Abstract][Full Text] [Related]
7. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease.
Plettenberg H; Assmann T; Ruzicka T
Arch Dermatol; 2003 May; 139(5):651-4. PubMed ID: 12756103
[No Abstract] [Full Text] [Related]
8. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
Fishman P; Merimski O; Baharav E; Shoenfeld Y
Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.
Gregg RK; Nichols L; Chen Y; Lu B; Engelhard VH
J Immunol; 2010 Feb; 184(4):1909-17. PubMed ID: 20083666
[TBL] [Abstract][Full Text] [Related]
10. Apigenin protects melanocytes and improve tyrosinase activity in a hydroquinone induced vitiligo mouse model targeting P38 MAP kinase signaling: histopathology and immunohistochemistry analysis.
Chauhan K; Goel F; Singh S
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4859-4869. PubMed ID: 38157025
[TBL] [Abstract][Full Text] [Related]
11. Irreversibly inhibitory kinetics of 3,5-dihydroxyphenyl decanoate on mushroom (Agaricus bisporus) tyrosinase.
Qiu L; Chen QX; Wang Q; Huang H; Song KK
Bioorg Med Chem; 2005 Nov; 13(22):6206-11. PubMed ID: 16039860
[TBL] [Abstract][Full Text] [Related]
12. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay.
Kemp EH; Gawkrodger DJ; MacNeil S; Watson PF; Weetman AP
J Invest Dermatol; 1997 Jul; 109(1):69-73. PubMed ID: 9204957
[TBL] [Abstract][Full Text] [Related]
13. Biological responses in Balb/c mice after long-term parenteral administration of the light subunit of mushroom tyrosinase.
Ismaya WT; Efthyani A; Tjandrawinata RR; Rachmawati H
J Biochem Mol Toxicol; 2017 Nov; 31(11):. PubMed ID: 28700109
[TBL] [Abstract][Full Text] [Related]
14. [Effect of zibuganshenfang on the expression and activity of tyrosinase on B16 cells].
Zhao J; Zhang L; Li P; Liu X; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Sep; 36(18):2567-70. PubMed ID: 22256768
[TBL] [Abstract][Full Text] [Related]
15. Enzyme, protein, carbohydrate, and phenolic contaminants in commercial tyrosinase preparations: potential problems affecting tyrosinase activity and inhibition studies.
Flurkey A; Cooksey J; Reddy A; Spoonmore K; Rescigno A; Inlow J; Flurkey WH
J Agric Food Chem; 2008 Jun; 56(12):4760-8. PubMed ID: 18500813
[TBL] [Abstract][Full Text] [Related]
16. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).
Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128
[TBL] [Abstract][Full Text] [Related]
17. Mushroom tyrosinase: recent prospects.
Seo SY; Sharma VK; Sharma N
J Agric Food Chem; 2003 May; 51(10):2837-53. PubMed ID: 12720364
[TBL] [Abstract][Full Text] [Related]
18. Production of o-diphenols by immobilized mushroom tyrosinase.
Marín-Zamora ME; Rojas-Melgarejo F; García-Cánovas F; García-Ruiz PA
J Biotechnol; 2009 Jan; 139(2):163-8. PubMed ID: 19047003
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin?
Prignano F; Betts CM; Lotti T
J Electron Microsc (Tokyo); 2008 Jan; 57(1):25-31. PubMed ID: 18174263
[TBL] [Abstract][Full Text] [Related]
20. [Etiopathogenesis of acquired vitiligo].
Mylek D; Wojas K
Przegl Dermatol; 1976; 63(5):715-20. PubMed ID: 826985
[No Abstract] [Full Text] [Related]
[Next] [New Search]
